Helping healthcare professionals to support patients

Shingles Awareness Week 2024: Accelerating immunisation in your most vulnerable patients

This is a promotional webinar organised and funded by GSK for Healthcare professionals and other relevant decision makers only.

Adverse event reporting statement is at the foot of this page.

Join us on 29th February 2024 at 13:00 or 18:30 for our expert led webinar where we will be discussing Shingles Awareness Week, and the impact of shingles on severely immunocompromised patients. Click 'register now' to register and learn more.

Prescribing Information (GB & NI)

February 2024 | PM-GB-SGX-WCNT-230049 (V1.0)

Featured products

Links to prescribing information at bottom of page.

More resources

Get more from GSKpro

Get access to free patient resources including demo devices, exclusive webinars on the topics that matter to you and more.

Prescribing information

Trelegy Ellipta prescribing information

Nucala prescribing information

Zejula prescribing information (GB)

Zejula prescribing information (NI)

SHINGRIX prescribing information (GB)

SHINGRIX prescribing information (NI)

Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellowcard in the Google Play or Apple App Store. Adverse events should also be reported to GSK on 0800 221 441 or

February 2024 | PM-GB-NA-WCNT-210014 (V7.0)